Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 5/20 | 0.35 |
| ▸ | MET | P08581 | 3/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 2/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613048 | 0.86 | TSHR (0.35) | GRM4MAPK1TSHRCCNT1CDK9 | |
| SCHEMBL25624362 | 0.85 | CDK1 (0.34) | — | |
| SCHEMBL25626737 | 0.84 | LRRK2 (0.34) | — | |
| SCHEMBL25627364 | 0.83 | MAP3K7 (0.33) | — | |
| SCHEMBL25624436 | 0.81 | GRM4 (0.33) | GRM4 | |
| SCHEMBL25624526 | 0.81 | CYP2C19 (0.40) | — | |
| SCHEMBL25624363 | 0.80 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL25650927 | 0.77 | CDK1 (0.33) | — | |
| SCHEMBL25624233 | 0.74 | LRRK2 (0.30) | — | |
| SCHEMBL25624105 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | MERTK 2676/4885MET 1759/4885GRM4 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.